Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Population-level forecasting of CAR-T–related toxicities using meta-analytic data.

Nimra Shafi, Madho Mal, Syed Hassan Ali et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18602

e18602 Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment of hematologic malignanc...

Contemporary trends in early-stage non–small cell lung cancer diagnosis and disparities, 2018–2022.

Ahmed Minhas Jun 01, 2026 pp. 10550-10550 10.1200/jco.2026.44.16_suppl.10550

10550 Background: Early detection of non-small cell lung cancer (NSCLC) improves survival. We evaluated stage trends in ad...

Real-world evaluation of CXCL9/10 with PD-L1 and TMB as predictors of pembrolizumab benefit in triple-negative breast cancer (TNBC).

Shipra Gandhi, Sachin Kumar Deshmukh, Madison T. Canning et al. Jun 01, 2026 pp. 1125-1125 10.1200/jco.2026.44.16_suppl.1125

1125 Background: Pembrolizumab is approved for TNBC; however, current biomarkers PD-L1 and tumor mutational burden (TMB) h...

Rural and urban disparities in cancer mortality in Texas during the COVID-19 pandemic.

Haris Majeed, George Kypriotakis Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22504

e22504 Background: Populations residing in rural regions (in comparison to urban) often experience higher cancer mortality...

Radiogenomic biomarkers for identifying surgery-sparing candidates in locally advanced gastric or gastro-esophageal junction cancer treated with perioperative immunochemotherapy: A discovery and validation study.

Song-Bin Guo, Xiaopeng Tian, Hailong Li et al. Jun 01, 2026 pp. 4058-4058 10.1200/jco.2026.44.16_suppl.4058

4058 Background: Perioperative immunochemotherapy has markedly increased pathologic complete remission (pCR) rates in pati...

A meta-analysis on outcomes of zanidatamab plus chemotherapy in patients with advanced HER2-gastroesophageal adenocarcinoma.

Henrique Jin Son Kim, Leonardo Gil Santana, Murilo Lauria Freire Ribeiro et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16076

e16076 Background: Zanidatamab is a novel HER2-targeted antibody that binds to two non-overlapping extracellular domains o...

Delayed time to treatment initiation among patients with HPV-associated oropharyngeal squamous cell carcinoma, 2011–2024.

Onyema Chido-Amajuoyi, Qin Sun, Lauren Shih et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18091

e18091 Background: Delays in time to treatment initiation (TTI) has been shown to have a negative impact on cancer outcome...

Hidden advanced physiology in non-metastatic gastrointestinal cancer: Malnutrition/cachexia and in-patient failure-to-rescue.

Wei Ju Lin, Ramaditya Srinivasmurthy, Rishi Kumar Nanda et al. Jun 01, 2026 pp. 11102-11102 10.1200/jco.2026.44.16_suppl.11102

11102 Background: Cancer stage is often used as a proxy for inpatient risk, yet physiologic reserve may better determine o...

Comparison of immediate and delayed autologous breast reconstruction methods: A retrospective cohort study.

Ilona Duadze, Azizzhon Zikiryakhodzhaev, Andrey Kaprin Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12739

e12739 Background: Breast reconstruction using autologous flaps is currently the gold standard in breast reconstructive pl...

Prognostic impact of MRD positivity at ultra-sensitive ctDNA levels using a WGS-based personalized assay: A pan-cancer analysis from MONSTAR-SCREEN-3.

Tadayoshi Hashimoto, Shin Kobayashi, Eiji Oki et al. Jun 01, 2026 pp. 3044-3044 10.1200/jco.2026.44.16_suppl.3044

3044 Background: While circulating tumor DNA (ctDNA) demonstrates promise as a molecular residual disease (MRD) biomarker,...

Stage-dependent metabolic reprogramming in treatment-naïve lung adenocarcinoma: From oxidative flexibility to glycolytic entrapment.

Alexandre Tavartkiladze, Pati Revazishvili, Levan Tavartkiladze Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20566

e20566 Background: Lung adenocarcinoma demonstrates metabolic reprogramming during progression, frequently shifting from m...

Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.

Atulya Aman Khosla, Parth Dhamelia, Yagnapriya Ammakola et al. Jun 01, 2026 pp. 2028-2028 10.1200/jco.2026.44.16_suppl.2028

2028 Background: Patients with EGFR-mutated non–small cell lung cancer (NSCLC) frequently develop BM, and CNS progression...

Association of facility type and metastatic burden with survival in gastric adenocarcinoma: A National Cancer Database study.

Yazmin Reategui-Almonacid, Daniel Moncada, Nkengeh Tazinkeng et al. Jun 01, 2026 pp. 11065-11065 10.1200/jco.2026.44.16_suppl.11065

11065 Background: While we know metastatic burden dictates survival in gastric adenocarcinoma (GA), how this intersects wi...

National trends and disparities in esophageal cancer and respiratory failure mortality among adults aged ≥45 years in the United States, 1999–2024: A CDC WONDER analysis.

Momna Warraich, Zain Ali, Taha Bin Nayyar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16021

e16021 Background: Esophageal cancer (EC) remains highly lethal in the United States, with approximately 22,370 new cases...

Comparative effectiveness of antibody-drug conjugates and targeted therapies in acute myeloid leukemia: A network meta-analysis of 15,412 patients.

Shankar Biswas, Gaurav Kansal, Yashasvi Srivastava et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18535

e18535 Background: Front-line AML treatment now includes antibody–drug conjugates and targeted therapies. However, relativ...

SHR-A2102, a Nectin-4 targeted antibody-drug conjugate, combined with HRS-4642 in previously treated pancreatic ductal adenocarcinoma harboring KRAS G12D mutation.

Jin Xu, Si Shi, Miaoyan Wei et al. Jun 01, 2026 pp. 4191-4191 10.1200/jco.2026.44.16_suppl.4191

4191 Background: Patients (pts) with previously treated advanced pancreatic ductal adenocarcinoma (PDAC) have limited opti...

Effects of resorcinol isoprenyl benzene derivative IPI201 on natural killer cell cytotoxicity and tumor cell viability in human colorectal adenocarcinoma cells.

Brett Lanier, Deborah Mosca, Herbert Neuman et al. Jun 01, 2026 pp. 2545-2545 10.1200/jco.2026.44.16_suppl.2545

2545 Background: Natural killer (NK) cells play a critical role in anti-tumor immunity, yet their cytotoxic efficacy can b...

Electrolyte abnormalities and severity, mortality, and resource utilization in U.S. cancer hospitalizations: National Inpatient Sample, 2018–2022.

Jacob Everett, Priam Chaganlal, Daniel Thomas Jones et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23190

e23190 Background: Electrolyte abnormalities are common during cancer hospitalizations and are often managed as isolated d...

Economic value of romiplostim for management of chemotherapy-induced thrombocytopenia in gastrointestinal cancers in the United States.

Shaimaa Elshafie, Mohammed Zuber, David Naveda et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23153

e23153 Background: Chemotherapy-induced thrombocytopenia (CIT) is a common complication of multiagent chemotherapy that ma...

Improving timeliness of radiology imaging scheduling at a comprehensive cancer center: A quality improvement initiative.

Sushrruti Varatharaj, Bernard Tawfik Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23283

e23283 Background: Timely radiologic imaging is essential for diagnosis, staging, and treatment monitoring in oncology car...

Segment-level molecular characterization of the proximal colon in TCGA colon adenocarcinoma.

Kashif Osmani, Ece Mutlu, Lucille Ray Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15737

e15737 Background: Colon adenocarcinoma is biologically heterogeneous and is commonly summarized using binary tumor sidedn...

Prognostic factors for survival outcomes in stage III cervical cancer patients receiving definitive (chemo)radiotherapy in Indonesia: A retrospective study.

Yoga Dwi Oktavianda, Widyastuti Widyastuti, Irwan Ramli et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17501

e17501 Background: Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced cervical cancer (LAC...

Palliative care utilization and outcomes among hospitalized cancer patients with severe non–cancer-related complications.

Aqsa Zoey Sorathia, Canan Dilay Dirican, Hasan Munshi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24084

e24084 Background: Cancer patients hospitalized with acute non-oncologic complications experience substantial morbidity, m...

Geographic disparities in surveillance adherence among individuals with <i>DICER1</i> pathogenic variants.

Angela Parra Del Riego, Casey Mehrhoff, Luke Devon Maese et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22656

e22656 Background: Individuals with pathogenic DICER1 variants require lifelong su...

Leukemia mortality in Latin America and the United States: A population-based analysis.

Leticia Campoverde, Bryan S. Valcarcel, Luis Malpica et al. Jun 01, 2026 pp. 1597-1597 10.1200/jco.2026.44.16_suppl.1597

1597 Background: Leukemia outcomes depend on timely diagnosis, specialized care, and access to effective therapies. Despit...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page